Premium
Paclitaxel‐based chemotherapy for aggressive kaposiform hemangioendothelioma of the temporomastoid region: Case report and review of the literature
Author(s) -
Funato Michinori,
Fukao Toshiyuki,
Sasai Hideo,
Hori Tomohiro,
Terazawa Daisuke,
Kanda Kaori,
Ozeki Michio,
Mizuta Keisuke,
Hirose Yoshinobu,
Kaneko Hideo,
Kondo Naomi
Publication year - 2013
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.23107
Subject(s) - medicine , chemotherapy , hemangioendothelioma , head and neck , surgery , paclitaxel , radiation therapy , oncology , radiology
Background Kaposiform hemangioendothelioma (KHE) is a rare vascular tumor of infancy and childhood. This tumor results in poor prognosis, and therefore, development of a more effective treatment is needed. Methods and Results We describe an 11‐year‐old boy presenting with left facial palsy caused by aggressive KHE of the left temporomastoid region. He was treated with paclitaxel‐based chemotherapy, because of the difficulty with complete surgical resection for anatomic factor, multiple lung metastases on diagnosis, and no response to conventional treatments. This treatment reduced the volume of primary tumor and lung metastatic lesions, but the efficacy was transitory. Conclusions Paclitaxel‐based chemotherapy for aggressive KHE may be effective, therefore the multimodality therapy including paclitaxel of aggressive KHE, particularly in the head and neck, needs to be investigated in further studies. © 2012 Wiley Periodicals, Inc. Head Neck, 2013